Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target entry represents a composite of two distinct bacterial components: the 50S ribosomal subunit and microbial DNA. The 50S ribosomal subunit is the larger component of the bacterial 70S ribosome, primarily composed of 23S and 5S ribosomal RNA (rRNA) and associated proteins. It serves as the site for peptidyl transferase activity, which is essential for the elongation of polypeptide chains during protein translation (StatPearls, 2023). Various antibiotic classes, such as macrolides and oxazolidinones, target the 50S subunit to arrest bacterial growth by halting protein synthesis (NCBI, 2022). Microbial DNA, conversely, is the genetic material of the bacterium and is targeted by agents that either cause direct structural damage or inhibit enzymes required for DNA maintenance. For example, nitroimidazoles like metronidazole cause DNA strand breaks, while fluoroquinolones inhibit DNA gyrase and topoisomerase IV, effectively preventing DNA replication and transcription (PubMed, 2021; PubChem, 2024). While both are critical therapeutic targets for treating bacterial infections, they are structurally and functionally unrelated, and their combination into a single target designation is non-standard in pharmacological classification.
Inhibition of protein synthesis by binding to the 23S rRNA of the 50S subunit to block the exit tunnel or peptidyl transferase center; induction of DNA strand breakage or inhibition of DNA topoisomerases (DNA gyrase and Topoisomerase IV) to prevent DNA replication and transcription.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 50S ribosomal subunit and microbial DNA.